<DOC>
	<DOC>NCT00048724</DOC>
	<brief_summary>The objective of the study is to evaluate the safety and efficacy of PEG-Intron vs. no treatment for the prevention of disease progression in adult subjects with compensated cirrhosis secondary to chronic hepatitis C, who failed to respond to therapy with an a interferon plus ribavirin.</brief_summary>
	<brief_title>Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Age at entry 1865 years; Nonresponders to previous treatment (minimum of 3 months) with an alpha interferon plus ribavirin; Liver biopsy demonstrating cirrhosis Any other cause for liver disease other than chronic hepatitis C; History or presence of complications of cirrhosis; Alcohol or illicit drug abuse or treatment with methadone within the past 2 years; Diseases or conditions that could interfere with participation in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatitis C; Cirrhosis</keyword>
</DOC>